齐拉西酮与奋乃静治疗精神分裂症的临床疗效及安全性比较

Ziprasidone vs.Perphenazine in the Treatment of Schizophrenia

目的:比较齐拉西酮与奋乃静治疗精神分裂症的疗效和安全性。方法:将60例住院患者随机分为齐拉西酮组与奋乃静组,各30例,2组平均剂量分别为(111.6±32.3)、(18.3±8.1)mg·d-1,po,疗程均为8周,以阳性和阴性症状量表评价疗效、副反应量表评定不良反应。结果:齐拉西酮与奋乃静的总体疗效相当(P>0.05),但不良反应明显低于奋乃静。结论:齐拉西酮是一种安全、有效的抗精神病药,其不良反应少于奋乃静。

OBJECTIVE： To compare the therapeutic effectiveness and safety between ziprasidone and perphenazine in the treatment of schizophrenia. METHODS： A total of 60 patients with schizophrenia were randomly assigned to receive ziprasidone （111.6 ± 32.3） mg·d ^-1 po（ n = 30） or perphenazine （18.3 ± 8.1） mg · d^-1 po（ n = 30） for 8 consecutive weeks. Therapeutic effectiveness and adverse reactions in patients of both group were assessed using positive and negative syndrome scale and treatment emergent side effect scale, respectively. RESULTS： Ziprasidone and perphenazine were equivalent in total therapeutic efficacy （P 〈0.05）, but the incidence of adverse effects in ziprasidone group was markedly lower than in perphenazine group. CONCLUSION： As compared with perphenazine, ziprasidone is more effective and safe with less side effects in the treatment of schizophrenia.